Scinai Immunotherapeutics (SCNI) Free Cash Flow (2018 - 2024)

Scinai Immunotherapeutics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$1.1 million for Q4 2024.

• Free Cash Flow for Q4 2024 came in at -$1.1 million, up 51.43% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.1 million (up 50.62% YoY), and the FY2025 annual result was -$6.1 million, up 4.6% from the prior year.
• Free Cash Flow came in at -$1.1 million for Q4 2024 at Scinai Immunotherapeutics, up from -$2.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q4 2024 to a low of -$15.8 million in Q4 2020.
• The 5-year median for Free Cash Flow is -$2.2 million (2023), against an average of -$4.0 million.
• Across the five-year window, Free Cash Flow tumbled 1700.2% in 2020 and surged 87.08% in 2021, its largest moves.
• Scinai Immunotherapeutics' Free Cash Flow stood at -$15.8 million in 2020, then soared by 87.08% to -$2.0 million in 2021, then grew by 2.35% to -$2.0 million in 2022, then declined by 13.53% to -$2.3 million in 2023, then surged by 51.43% to -$1.1 million in 2024.
• The last three Free Cash Flow figures came in at -$1.1 million (Q4 2024), -$2.0 million (Q3 2024), and -$1.8 million (Q2 2024), per Business Quant data.